Results 61 to 70 of about 22,351 (243)

Fingolimod improves diffuse brain injury by promoting AQP4 polarization and functional recovery of the glymphatic system

CNS Neuroscience & Therapeutics
Diffuse brain injury (DBI) models are characterized by intense global brain inflammation and edema, which characterize the most severe form of TBI. In a previous experiment, we found that fingolimod promoted recovery after controlled cortical impact ...
Dongyi Feng, Tao Liu, Xinjie Zhang, Tangtang Xiang, Wanqiang Su, Wei Quan, Rongcai Jiang   +6 more
semanticscholar   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod

Journal of Neurology
Pediatric-onset Multiple Sclerosis (POMS) patients show more inflammatory disease compared with adult-onset MS. However, highly effective treatments are limited with only fingolimod being approved in Italy and natalizumab prescribed as off-label ...
A. Carotenuto, Cristina di Monaco, L. Papetti, G. Borriello, E. Signoriello, C. Masciulli, Valentina Tomassini, G. De Luca, A. Ianniello, G. Lus, Federica Novarella, A. Spiezia, Dario Di Somma, M. Moccia, M. Petracca, C. Iacovazzo, G. Servillo, E. Portaccio, M. Triassi, M. Amato, C. Pozzilli, M. Valeriani, V. Brescia Morra, R. Lanzillo   +23 more
semanticscholar   +1 more source

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models

International Journal of Molecular Sciences, 2022
New therapies are required for patients with non-small cell lung cancer (NSCLC) for which the current standards of care poorly affect the patient prognosis of this aggressive cancer subtype.
T. Rupp, Solène Debasly, Laurie Genest, G. Froget, V. Castagné   +4 more
semanticscholar   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Exploring the molecular targets of fingolimod and siponimod for treating the impaired cognition of schizophrenia using network pharmacology and molecular docking

Schizophrenia
The treatment of cognitive impairment in schizophrenia is an unaddressed need due to the absence of novel treatments. Recent studies demonstrated that fingolimod and siponimod have neuroprotective effects in several neuropsychiatric disorders; however ...
Chao Li, C. Zhuo, Xiaoyan Ma, Ranli Li, Ximing Chen, Yachen Li, Qiuyu Zhang, Lei-Xiang Yang, Lina Wang   +8 more
semanticscholar   +1 more source

Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study

BMJ Neurology Open, 2022
Background In the PARADIGMS Study, fingolimod demonstrated superior efficacy versus interferon (IFN) β-1a and comparable overall incidence of adverse events but slightly higher rate of serious adverse events in patients with paediatric-onset multiple ...
L. Krupp, B. Banwell, T. Chitnis, K. Deiva, Jutta Gaertner, A. Ghezzi, P. Huppke, E. Waubant, Virginia DeLasHeras, A. Azmon, R. Karan   +10 more
semanticscholar   +1 more source

Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing. [PDF]

PLoS ONE, 2015
In multiple sclerosis (MS) patients, Fingolimod may induce prolonged heart-rate slowing which might be caused by MS-related central autonomic lesions.To evaluate whether MS-patients with prolonged heart-rate slowing (> six hours) upon Fingolimod show ...
Max J Hilz, Tassanai Intravooth, Sebastian Moeller, Ruihao Wang, De-Hyung Lee, Julia Koehn, Ralf A Linker   +6 more
doaj   +1 more source

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi, Sola Al Ghazal, Salem Hannoun, Medhat A. Siddik, Nour M. Najjar, Jim Dagher, Joseph Abboud, Myriam G. Semaan, Samia J. Khoury   +8 more
wiley   +1 more source

Fingolimod in pediatric multiple sclerosis:three case reports [PDF]

, 2021
Treatment for pediatric-onset multiple sclerosis (POMS) currently reflects treatment for adult-onset MS, despite some differences in its clinical course.
Valeriani, Massimiliano, Ferilli, Michela Ada Noris, Papetti, Laura   +2 more
core   +1 more source